Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.480
Sell
RSI(14)
40.997
Neutral
STOCH(KDJ)(9,3,3)
21.307
Neutral
ATR(14)
1.162
High Vlolatility
CCI(14)
-144.140
Sell
Williams %R
69.114
Sell
TRIX(12,20)
-0.355
Sell
StochRSI(14)
65.718
Buy
Celldex Therapeutics Inc
CLDX23.760USD
+1.180+5.23%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.58BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Celldex Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Celldex Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 69 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 52.31.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Celldex Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Celldex Therapeutics Inc Highlights
StrengthsRisks
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 197.84% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.02M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 7.02M.
Overvalued
The company’s latest PE is -7.02, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 73.56M shares, increasing 2.11% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 40.78K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.51.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
52.308
Target Price
+131.65%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Celldex Therapeutics Inc is 5.80, ranking 323 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 59.17%.
Score
Financials
6.50
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.36
Operational Efficiency
2.57
Growth Potential
5.45
Shareholder Returns
7.11
Celldex Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Celldex Therapeutics Inc is 6.88, ranking 206 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.02, which is -20.28% below the recent high of -5.59 and -182.14% above the recent low of -19.80.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 69/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Celldex Therapeutics Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 53.00, with a high of 90.00 and a low of 21.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
52.308
Target Price
+131.65%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Celldex Therapeutics Inc
CLDX
16
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Celldex Therapeutics Inc is 6.69, ranking 191 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 27.06 and the support level at 21.39, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
24.088
Sell
MA10
24.730
Sell
MA20
25.402
Sell
MA50
26.408
Sell
MA100
26.054
Sell
MA200
23.799
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Celldex Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 131.89%, representing a quarter-over-quarter increase of 0.56%. The largest institutional shareholder is The Vanguard, holding a total of 4.01M shares, representing 6.04% of shares outstanding, with 3.18% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Wellington Management Company, LLP
Kynam Capital Management LP
BlackRock Institutional Trust Company, N.A.
Bellevue Asset Management AG
Fidelity Management & Research Company LLC
Commodore Capital LP
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Celldex Therapeutics Inc is 6.08, ranking 30 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.22. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Celldex Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
1.22
VaR
+5.47%
240-Day Maximum Drawdown
+29.07%
240-Day Volatility
+62.69%
Return
Best Daily Return
60 days
+7.72%
120 days
+7.72%
5 years
+27.76%
Worst Daily Return
60 days
-6.96%
120 days
-13.03%
5 years
-15.80%
Sharpe Ratio
60 days
+0.01
120 days
-0.14
5 years
+0.19
Risk Assessment
Maximum Drawdown
240 days
+29.07%
3 years
+70.84%
5 years
+73.11%
Return-to-Drawdown Ratio
240 days
+0.39
3 years
-0.16
5 years
-0.06
Skewness
240 days
+0.51
3 years
+0.97
5 years
+0.80
Volatility
Realised Volatility
240 days
+62.69%
5 years
+65.29%
Standardised True Range
240 days
+5.28%
5 years
+7.45%
Downside Risk-Adjusted Return
120 days
-21.28%
240 days
-21.28%
Maximum Daily Upside Volatility
60 days
+39.47%
Maximum Daily Downside Volatility
60 days
+29.44%
Liquidity
Average Turnover Rate
60 days
+1.80%
120 days
+1.56%
5 years
--
Turnover Deviation
20 days
+50.55%
60 days
+22.39%
120 days
+6.49%
Peer Comparison
Biotechnology & Medical Research
Celldex Therapeutics Inc
CLDX
7.03 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
